Peroxisome proliferator-activated receptor-gamma activation reverses pulmonary arterial hypertension in an animal model, highlighting a potential therapeutic target linked to insulin resistance.
Links metabolic factors to PAH in animals; hypothesis-generating for PPAR-gamma agonists, requiring human trials before any clinical consideration.
We have shown that insulin resistance, low plasma adiponectin levels, and deficiency of apoE may be risk factors for PAH and that peroxisome proliferator-activated receptor-gamma activation can reverse PAH in an animal model.
No takes yet. Share an insight, caveat, or question.
Hansmann et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: